Fat in the liver and insulin resistance

References

• Yki‐Järvinen H. Insulin resistance in type 2 diabetes. Textbook of Diabetes. 2nd ed, J. C Pickup, G Williams. Blackwell, Oxford 2003; 22.1–22.19
   Google Scholar
• Reitman M. L., Arioglu E., Gavrilova O., Taylor S. I. Lipoatrophy revisited. Trends Endocrinol Metab 2000; 11: 410–6
   PubMed Web of Science ®Google Scholar
• Kim J. K., Fillmore J. J., Chen Y., Yu C., Moore I. K., Pypaert M., et al. Tissue‐specific overexpression of lipoprotein lipase causes tissue‐specific insulin resistance. Proc Natl Acad Sci U S A 2001; 98: 7522–7
   PubMed Web of Science ®Google Scholar
• Westerbacka J., Corner A., Tiikkainen M., Tamminen M., Vehkavaara S., Hakkinen A. M., et al. Women and men have similar amounts of liver and intra‐abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 2004; 47: 1360–9
   PubMed Web of Science ®Google Scholar
• Yki‐Jarvinen H., Sutinen J., Silveira A., Korsheninnikova E., Fisher R., Kannisto K., et al. Regulation of Plasma PAI‐1 Concentrations in HAART‐Associated Lipodystrophy During Rosiglitazone Therapy. Arterioscler Thromb Vasc Biol 2003; 23: 688–94
   PubMed Web of Science ®Google Scholar
• Cigolini M., Targher G., Agostino G., Tonoli M., Muggeo M., De Sandre G. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men – role of the metabolic syndrome. Thromb Haemost 1996; 76: 69–73
   Google Scholar
• Kerner A., Avizohar O., Sella R., Bartha P., Zinder O., Markiewicz W., et al. Association between elevated liver enzymes and C‐reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005; 25: 193–7
   PubMed Web of Science ®Google Scholar
• Clark J. M., Brancati F. L., Diehl A. M. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649–57
   PubMed Web of Science ®Google Scholar
• Reitman M. L. Metabolic lessons from genetically lean mice. Annu Rev Nutr 2002; 22: 459–82
   PubMedGoogle Scholar
• Moitra J., Mason M. M., Olive M., Krylov D., Gavrilova O., Marcus‐Samuels B., et al. Life without white fat: a transgenic mouse. Genes Dev 1998; 12: 3168–81
   PubMed Web of Science ®Google Scholar
• Kim J. K., Gavrilova O., Chen Y., Reitman M. L., Shulman G. I. Mechanism of insulin resistance in A‐ZIP/F‐1 fatless mice. J Biol Chem 2000; 275: 8456–60
   PubMedGoogle Scholar
• Gavrilova O., Marcus‐Samuels B., Graham D., Kim J. K., Shulman G. I., Castle A. L., et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000; 105: 271–8
   PubMed Web of Science ®Google Scholar
• Carr A., Cooper D. A. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423–30
   PubMed Web of Science ®Google Scholar
• Gulick R. M., Mellors J. W., Havlir D., Eron J. J., Gonzalez C., McMahon D., et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734–9
   PubMed Web of Science ®Google Scholar
• Seppala‐Lindroos A., Vehkavaara S., Hakkinen A. M., Goto T., Westerbacka J., Sovijarvi A., et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023–8
   PubMed Web of Science ®Google Scholar
• Tiikkainen M., Tamminen M., Hakkinen A. M., Bergholm R., Vehkavaara S., Halavaara J., et al. Liver‐fat accumulation and insulin resistance in obese women with previous gestational diabetes. Obes Res 2002; 10: 859–67
   Google Scholar
• Wasastjerna C., Reissell P., Karjalainen J., Ekelund P. Fatty liver in diabetes. A cytological study. Acta Med Scand 1972; 191: 225–8
   PubMedGoogle Scholar
• Ryysy L., Häkkinen A. M., Goto T., Vehkavaara S., Westerbacka J., Halavaara J., et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49: 749–58
   PubMed Web of Science ®Google Scholar
• Lemieux S., Prud'homme D., Bouchard C., Tremblay A., Despres J. P. Sex differences in the relation of visceral adipose tissue accumulation to total body fatness. Am J Clin Nutr 1993; 58: 463–7
   PubMed Web of Science ®Google Scholar
• Szczepaniak L. S., Babcock E. E., Schick F., Dobbins R. L., Garg A., Burns D. K., et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 1999; 276: E977–89
   Web of Science ®Google Scholar
• Longo R., Ricci C., Masutti F., Vidimari R., Croce L. S., Bercich L., et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 1993; 28: 297–302
   PubMed Web of Science ®Google Scholar
• Joy D., Thava V. R., Scott B. B. Diagnosis of fatty liver disease: is biopsy necessary?. Eur J Gastroenterol Hepatol 2003; 15: 539–43
   PubMed Web of Science ®Google Scholar
• Piekarski J., Goldberg H. I., Royal S. A., Axel L., Moss A. A. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology 1980; 137: 727–9
   PubMedGoogle Scholar
• Fong D. G., Nehra V., Lindor K. D., Buchman A. L. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000; 32: 3–10
   PubMed Web of Science ®Google Scholar
• Burt A. D., Mutton A., Day C. P. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol 1998; 15: 246–58
   PubMed Web of Science ®Google Scholar
• Falck‐Ytter Y., Younossi Z. M., Marchesini G., McCullough A. J. Clinical features and natural history of non‐alcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17–26
   PubMed Web of Science ®Google Scholar
• Diehl A. M. Nonalcoholic steatohepatitis. Semin Liver Dis 1999; 19: 221–9
   PubMed Web of Science ®Google Scholar
• Clark J. M., Brancati F. L., Diehl A. M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960–7
   PubMed Web of Science ®Google Scholar
• Schaffner F. Nonalcoholic fatty liver. Bockus Gastroenterology. 5th ed, W. S Haubrich, F Schaffner, J. E Berk. W.B. Saunders Company, Philadelphia 1995; 2246–54
   Google Scholar
• Frayn K. N. Visceral fat and insulin resistance–causative or correlative?. Br J Nutr 2000; 83 Suppl 1: S71–7
   Google Scholar
• Nielsen S., Guo Z., Johnson C. M., Hensrud D. D., Jensen M. D. Splanchnic lipolysis in human obesity. J Clin Invest 2004; 113: 1582–8
   PubMed Web of Science ®Google Scholar
• Klein S. The case of visceral fat: argument for the defense. J Clin Invest 2004; 113: 1530–2
   PubMed Web of Science ®Google Scholar
• Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose‐specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79–83
   PubMed Web of Science ®Google Scholar
• Sutinen J., Korsheninnikova E., Funahashi T., Matsuzawa Y., Nyman T., Yki‐Järvinen H. Circulating Concentration of Adiponectin and Its Expression in Subcutaneous Adipose Tissue in Patients with Highly Active Antiretroviral Therapy‐Associated Lipodystrophy. J Clin Endocrinol Metab 2003; 88: 1907–10
   PubMed Web of Science ®Google Scholar
• Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat‐derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941–6
   PubMed Web of Science ®Google Scholar
• Xu A., Wang Y., Keshaw H., Xu L. Y., Lam K. S., Cooper G. J. The fat‐derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91–100
   PubMed Web of Science ®Google Scholar
• Tiikkainen M., Häkkinen A‐M., Korsheninnikova E., Nyman T., Mäkimattila S., Yki‐Järvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169–7
   PubMed Web of Science ®Google Scholar
• Pajvani U. B., Hawkins M., Combs T. P., Raja M. W., Doebber T., Berger J. P., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione‐mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152–62
   PubMed Web of Science ®Google Scholar
• Bajaj M., Suraamornkul S., Piper P., Hardies L. J., Glass L., Cersosimo E., et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone‐treated type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 200–6
   PubMed Web of Science ®Google Scholar
• Johanson E. H., Jansson P. A., Lonn L., Matsuzawa Y., Funahashi T., Taskinen M. R., et al. Fat distribution, lipid accumulation in the liver, and exercise capacity do not explain the insulin resistance in healthy males with a family history for type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 4232–8
   Google Scholar
• Weisberg S. P., McCann D., Desai M., Rosenbaum M., Leibel R. L., Ferrante A. W, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796–808
   PubMed Web of Science ®Google Scholar
• Hoffstedt J., Arvidsson E., Sjolin E., Wahlen K., Arner P. Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance. J Clin Endocrinol Metab 2004; 89: 1391–6
   PubMed Web of Science ®Google Scholar
• Kern P. A., Ranganathan S., Li C., Wood L., Ranganathan G. Adipose tissue tumor necrosis factor and interleukin‐6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745–51
   PubMed Web of Science ®Google Scholar
• Bastard J. P., Caron M., Vidal H., Jan V., Auclair M., Vigouroux C., et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV‐1‐infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359: 1026–31
   PubMed Web of Science ®Google Scholar
• Bruun J. M., Lihn A. S., Verdich C., Pedersen S. B., Toubro S., Astrup A., et al. Regulation of adiponectin by adipose tissue‐derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285: E527–33
   PubMed Web of Science ®Google Scholar
• Pajvani U. B., Du X., Combs T. P., Berg A. H., Rajala M. W., Schulthess T., et al. Structure‐function studies of the adipocyte‐secreted hormone Acrp30/adiponectin: Implications for metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073–85
   PubMed Web of Science ®Google Scholar
• Samuel V. T., Liu Z. X., Qu X., Elder B. D., Bilz S., Befroy D., et al. Mechanism of hepatic insulin resistance in non‐alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345–53
   PubMed Web of Science ®Google Scholar
• Chao L., Marcus‐Samuels B., Mason M. M., Moitra J., Vinson C., Arioglu E., et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 2000; 106: 1221–8
   PubMed Web of Science ®Google Scholar
• Watkins S. M., Reifsnyder P. R., Pan. H., German J. B., Leiter E. H. Lipid metabolome‐wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res 2002; 43: 1809–17
   PubMed Web of Science ®Google Scholar
• Clark J. M., Diehl A. M., Brancati F. L. Nonalcoholic fatty liver disease and the risk of type 2 diabetes in the United States. Diabetes 2001; 50: A38, Abstract
   Google Scholar
• Meltzer A. A., Everhart J. E. Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans. Am J Epidemiol 1997; 146: 565–71
   PubMed Web of Science ®Google Scholar
• Ohlson L. O., Larsson B., Bjorntorp P., Eriksson H., Svardsudd K., Welin L., et al. Risk factors for type 2 (non‐insulin‐dependent) diabetes mellitus. Thirteen and one‐half years of follow‐up of the participants in a study of Swedish men born in 1913. Diabetologia 1988; 31: 798–805
   PubMed Web of Science ®Google Scholar
• Perry I. J., Wannamethee S. G., Shaper A. G. Prospective study of serum gamma‐glutamyltransferase and risk of NIDDM. Diabetes Care 1998; 21: 732–7
   PubMed Web of Science ®Google Scholar
• Nakanishi N., Nishina K., Li W., Sato M., Suzuki K., Tatara K. Serum gamma‐glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle‐aged Japanese men. J Intern Med 2003; 254: 287–95
   PubMedGoogle Scholar
• Lee D. H., Jacobs D. R, Jr., Gross M., Kiefe C. I., Roseman J., Lewis C. E., et al. Gamma‐glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2003; 49: 1358–66
   PubMed Web of Science ®Google Scholar
• Lee D. H., Ha M. H., Kim J. H., Christiani D. C., Gross M. D., Steffes M., et al. Gamma‐glutamyltransferase and diabetes–a 4 year follow‐up study. Diabetologia 2003; 46: 359–64
   PubMed Web of Science ®Google Scholar
• Hanley A. J., Williams K., Festa A., Wagenknecht L. E., D'Agostino R. B, Jr., Kempf J., et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004; 53: 2623–32
   PubMed Web of Science ®Google Scholar
• Vozarova B., Stefan N., Lindsay R. S., Saremi A., Pratley R. E., Bogardus C., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51: 1889–95
   PubMed Web of Science ®Google Scholar
• De M. R., Locatelli F., Zoppini G., Verlato G., Bonora E., Muggeo M. Cause‐specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999; 22: 756–61
   PubMed Web of Science ®Google Scholar
• El‐Serag H. B., Everhart J. E. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002; 122: 1822–8
   PubMed Web of Science ®Google Scholar
• El‐Serag H. B., Tran T., Everhart J. E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460–8
   PubMed Web of Science ®Google Scholar
• Jackson R. A., Hawa I. M., Jaspan J. B., Sim B. M., SiSilvio L., Flatherbe D., et al. Mechanism of metformin action in non‐insulin‐dependent diabetes. Diabetes 1987; 36: 632–40
   PubMed Web of Science ®Google Scholar
• Yki‐Järvinen H., Helve E., Sane T., Nurjhan N., Taskinen M‐R. Insulin inhibition of overnight glucose production and gluconeogenesis from lactate in NIDDM. Am J Physiol 1989; 256: E732–9
   Google Scholar
• Mitrakou A., Kelley D., Veneman T., Jenssen T., Pangburn T., Reilly T., et al. Contribution of abnormal muscle and liver metabolism to postprandial hyperglycemia in NIDDM. Diabetes 1990; 39: 1381–90
   PubMed Web of Science ®Google Scholar
• Scheen A. J., Luyckx F. H. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 2002; 16: 703–16
   PubMed Web of Science ®Google Scholar
• Tiikkainen M., Bergholm R., Vehkavaara S., Rissanen A., Hakkinen A. M., Tamminen M., et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003; 52: 701–7
   PubMedGoogle Scholar
• Mayerson A. B., Hundal R. S., Dufour S., Lebon V., Befroy D., Cline G. W., et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797–802
   PubMed Web of Science ®Google Scholar
• Bajaj M., Suraamornkul S., Pratipanawatr T., Hardies L. J., Pratipanawatr W., Glass L., et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52: 1364–70
   PubMed Web of Science ®Google Scholar
• Carey D. G., Cowin G. J., Galloway G. J., Jones N. P., Richards J. C., Biswas N., et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res 2002; 10: 1008–15
   PubMedGoogle Scholar
• Miyazaki Y., Mahankali A., Wajcberg E., Bajaj M., Mandarino L. J., DeFronzo R. A. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 4312–9
   PubMed Web of Science ®Google Scholar
• Sutinen J., Kannisto K., Korsheninnikova E., Fischer R. M., Ehrenborg E., Nyman T., et al. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy‐associated lipodystrophy. Am J Physiol Endocrinol Metab 2004; 286: E941–9
   PubMedGoogle Scholar
• Sutinen J., Häkkinen A‐M. . , Westerbacka J., Seppälä‐Lindroos A., Vehkavaara S., Halavaara J., et al. Rosiglitazone in the treatment of HAART‐associated lipodystrophy ‐ a randomized double‐blind placebo‐controlled study. Antiviral Ther 2003; 8: 199–207
   PubMed Web of Science ®Google Scholar
• Neuschwander‐Tetri B. A., Brunt E. M., Wehmeier K. R., Oliver D., Bacon B. R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐gamma ligand rosiglitazone. Hepatology 2003; 38: 1008–17
   PubMed Web of Science ®Google Scholar
• Promrat K., Lutchman G., Uwaifo G. I., Freedman R. J., Soza A., Heller T., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188–96
   PubMed Web of Science ®Google Scholar
• Yki‐Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106–18
   PubMed Web of Science ®Google Scholar
• Westerbacka J., Lammi K., Häkkinen A‐M., Rissanen A., Salminen I., Aro A., Yki‐Järvinen H. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005; 90: 2804–9
   PubMed Web of Science ®Google Scholar